Free tool
FAERS Monitor: Iqirvo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218860 or its brand name (Iqirvo, Elafibranor). Reports on generic versions are filed under their own applications.
Reports
900
Serious
235
26% of reports
Hospitalization
67
Death reported
36
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue100
- nausea86
- pruritus83
- diarrhoea74
- product dose omission issue72
- myalgia68
- constipation65
- weight increased61
- arthralgia57
- headache44
- off label use44
- dizziness43
- muscle spasms42
- abdominal pain upper38
- vomiting38
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2024 | 76 |
| 2025 | 400 |
| 2026 | 423 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,259 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myalgiaSignal | 68 | 9.4 | 7.4 | 503 |
| constipationSignal | 65 | 7.0 | 5.5 | 330 |
| weight increasedSignal | 61 | 6.4 | 5.0 | 273 |
| product dose omission issueSignal | 72 | 5.7 | 4.6 | 280 |
| muscle spasmsSignal | 42 | 5.3 | 4.0 | 145 |
| pruritusSignal | 83 | 5.0 | 4.1 | 270 |
| abdominal pain upperSignal | 38 | 4.3 | 3.2 | 94 |
| arthralgiaSignal | 57 | 3.2 | 2.5 | 86 |
| fatigueSignal | 100 | 3.0 | 2.5 | 137 |
| diarrhoeaSignal | 74 | 2.7 | 2.2 | 79 |
| nauseaSignal | 86 | 2.5 | 2.1 | 82 |
| dizzinessSignal | 43 | 2.0 | 1.5 | 21 |
| vomiting | 38 | 1.9 | 1.4 | 15 |
| headache | 44 | 1.6 | 1.2 | 11 |
| off label use | 44 | 1.2 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.